Abstract: Essential hypertension is a common, complex disorder affecting ≤1 billion adults globally. Blood pressure is a highly heritable trait, with ≤50% of the variation between individuals accounted for by familial relationships. Despite this strong heritability, determining the genetic architecture of hypertension in humans has proved challenging. Recent technological and methodological developments have given rise to what is now known as omics-a domain of study that includes genomics, as well as epigenomics, transcriptomics, proteomics, and metabolomics. For complex traits like hypertension, which involve multiple pathways and organs, omic approaches offer the advantage of allowing identification of novel hypertensive mechanisms to help further dissect and characterize the disorder's pathophysiology. This review provides a primer on the genomics, transcriptomics, proteomics, and metabolomics of blood pressure and hypertension. We provide an introduction to each approach with examples chosen to illustrate its potential. We conclude with a brief assessment of current methods aimed at integrating multiomic data. A review of the literature found genomic, epigenomic, transcriptomic, proteomic, and metabolomic methods have been applied to dissect the pathophysiology of blood pressure and hypertension. Omic methods and integration of multiomic data represent a potentially fruitful approach to illuminating the complex pathophysiology of hypertension and, ultimately, may point to novel diagnostics and treatments. (Circ Res.
ssential hypertension is a common, complex disorder affecting ≤1 billion adults globally. 1 Blood pressure (BP) is a highly heritable trait, with ≤50% of the variation between individuals accounted for by familial relationships. Despite this strong heritability, determining the genetic architecture of hypertension in humans has proved challenging, and in aggregate, most of the genomic discoveries of common variants affecting BP account for <4% of the between-person variation in the trait. Recent technological and methodological developments have given rise to what is now known as omics-a domain of study that includes genomics, as well as epigenomics, transcriptomics, proteomics, and metabolomics ( Figure 1 ). Omics as a whole holds the promise to provide a more complete and accurate picture of an organism's or species' molecular structure; a clearer understanding of the structure and function of molecules downstream from genomic processes may prove pivotal in our understanding of those processes. Rather than rely simply on specific genetic variants in candidate genes in known BP pathways, omic methods offer a global picture of all heritable factors influencing BP. For complex traits like hypertension, which involve multiple pathways and organs, omic approaches offer the advantage of allowing identification of novel hypertensive mechanisms to further dissect and characterize hypertension pathophysiology. Omic approaches may identify different etiologies of hypertension that have historically been subsumed under a particular monogenic form. In some domains, omics might provide better diagnostics that can be used to predict the severity of hypertension or target-organ damage associated with hypertension. In the future, omic approaches may personalize antihypertensive therapy for optimal response. The rapid advancement of omic technologies has led to intense interest in the field of multiomic statistical methods that aim to integrate these various kinds of data. Multiomic statistical approaches may provide the tools to unlock the mysteries of the omic determinants of hypertension.
This review provides a broad survey of the omics of BP and hypertension, including genomics, transcriptomics, proteomics, metabolomics, and multiomic methods. The discussion of each of these approaches is far from comprehensive, but we provide an introduction to each with examples chosen to illustrate its potential.
Genomics
Genomics, broadly defined, is the study of the structure and function of an organism's full complement of DNA, including all protein-coding and noncoding regions within genes (exons and introns, respectively) and intergenic DNA. Genetics, in contrast, refers to the study of individual genes. A simple PubMed search of titles and abstracts suggests that there have been nearly twice as many hypertension genomics publications as all other hypertension omics combined. Many early genetic studies of hypertension focused on Mendelian (or monogenic) disorders with comparatively well-characterized pathophysiologic chains. For example, glucocorticoid remediable aldosteronism results from an unequal crossing over between 2 closely related genes on chromosome 8 that are involved in adrenal steroid biosynthesis. Ultimately, this mutation increases aldosterone synthase activity, thereby increasing aldosterone, plasma volume, and BP. 2 Mendelian forms account for only a small fraction of the total burden of hypertension. Essential hypertension is polygenic in nature, and early candidate gene association studies were among the first to attempt to dissect the genetic architecture of the condition. By definition, however, these studies began with a priori suspicions of which genes may be involved in BP homeostasis. Genotyping was typically done by amplifying DNA segments by the polymerase chain reaction and hybridizing with an allele-specific oligonucleotide probe followed by a blot analysis. Some 50 candidate genes were routinely studied in the context of hypertension, including ADRA1B, 3 ADRB2, 3 ACE, 4 AGT, 5 and EDN1. 6 Many of these studies were characterized by lack of statistical power, confounding by environmental factors, and poorly defined phenotypes. As a result, the candidate gene era of hypertension genetics was characterized by frequent lack of replication and, often, contradictory findings among studies.
Although limited by their ability to pinpoint potentially causal genetic variants, linkage studies offered the first method to agnostically scan the genome for regions linked to a phenotype of interest. These family-based studies leveraged the phenomenon of genetic linkage-the tendency of DNA sequences near each other on the same chromosome to be inherited together-to measure the odds that a genetic marker and a phenotype were cosegregating because of linkage versus chance. Linkage studies of BP phenotypes were common and often subjected to large meta-analyses. The results of these studies were often mixed, with some optimistically reporting strong evidence of traits linked to specific chromosomal regions 7 and others reporting little. 8 Linkage studies largely fell out of favor before many of their findings could be fully explored as newer genome-wide genotyping technologies became available. Genome-wide association studies (GWAS) are noncandidate gene driven, able to agnostically scan the genome for associations between phenotypes and, typically, single-nucleotide polymorphisms (SNPs). GWAS use microarrays to genotype millions of SNPs. The microarrays contain allelespecific oligonucleotide probes affixed to a rigid surface. Specimen DNA sequences labeled with fluorescent dyes affix themselves to the probes. Laser-induced fluorescence is detected by an array scanner and these signal data are ultimately translated to genotype. This set of empirically measured genotypes can be augmented with millions of additional genotypes statistically inferred (ie, imputed) using known haplotypes. The typed or imputed SNPs with significant trait associations are unlikely to be functional variants but rather proxies in linkage disequilibrium with the functional SNP. As of this writing, the GWAS catalog listed >50 publications reporting GWAS studies of hypertension and BP-related traits. 9 Many GWAS findings have been novel-that is, pointing to genes not historically associated with BP homeostasis but biologically plausible. For example, in a GWAS of 1621 hypertensive cases and 1699 normotensive controls, Padmanabhan et al found significant associations with a variant in the UMOD and hypertension status. Although the function of the uromodulin protein is incompletely understood, UMOD is expressed primarily in the thick ascending limb of the loop of Henle where essential mechanisms of sodium handling are located. 10 Other GWAS have pointed to similarly novel candidates for further functional follow-up. 11, 12 Although BP and hypertension GWAS have proven useful in illuminating a few novel pathways, they have fallen short of expectations in many ways. Significantly associated and replicated variants identified in GWAS have limited utility as clinical biomarkers, even when incorporated into composite genetic risk scores. 13 Although it is estimated that 30% to 50% of variance in BP traits is attributable to genetic factors, only ≈2% of the phenotypic variance for systolic BP (SBP) and diastolic BP (DBP) can be explained by variants identified by GWAS. 11 Much has been written about the missing heritability of complex traits, such as BP and hypertension, 14 and it has been suggested that overestimates of heritability; underestimates of environmental contributions to heritability; poor understanding of the contributions of genetic interactions, epigenetics, and copy-number variants; and imprecise phenotyping may underlie the purported shortfall. The dominant paradigm informing the design of GWAS and the platforms used for SNP typing was that common heritable diseases (such as hypertension) were caused by common genetic variants. As a result, GWAS arrays assay predominantly variants with comparatively high minor allele frequencies. At least some of the missing heritability, many think, may be because of the unaccounted effects of functional rare variants. 15, 16 The SNP arrays used for GWAS genotype only a small subset of ≈3 billion base pairs in the human genome. DNA sequencing, as the name implies, has the potential to characterize every base in the genome. Initially, high costs limited studies to sequence only the protein-coding regions of the genome (whole-exome studies). In recent years, lower cost and higher performance of DNA sequencing methods have made whole-genome sequencing viable in studies large enough (ie, sufficiently powered) to detect trait associations with common and rare variants. To date, no whole-genome sequencing studies of BP have been published (although some are underway in the US National Institutes of Health TOPMed [Trans-Omics for Precision Medicine] program). Yu et al conducted a wholeexome study of SBP, DBP, pulse pressure, and mean arterial pressure in a sample of 17 956 individuals of African and European ancestry. Using a 2-stage analysis, they identified an assemblage of rare variants in the CLCN6 that were associated with lower DBP in both ancestry groups. The association was validated in a meta-analysis of the 2 stages in which CLCN6 was associated with lower DBP at exome-wide significance (P=5.0×10 −7 ). 17 Findings such as these create some optimism of what is yet to come in BP and hypertension genomics.
Epigenomics
Epigenomics concerns mechanisms that influence gene expression that are heritable but do not rely on differences in the base sequence of DNA. Epigenetic mechanisms include DNA methylation and post-translational histone modification (eg, acetylation and deacetylation), as well as mechanisms involving microRNAs and long noncoding RNAs (noted in the transcriptomics section below). Important epigenetic modifications occur during embryonic, fetal, and early development stages, as well as later in an organism's life. Because the epigenome interacts with the environment, studies of DNA methylation and histone modification can provide a dynamic, integrated schematic of disease pathophysiology and could potentially lead to the discovery of novel drug targets. And because epigenetic phenomena are both heritable and influenced by the environment, epigenetics offers a window into transgenerational effects of environmental exposures. Epigenetic mechanisms are cell-type specific, necessitating careful selection of sample tissue and vetting of protocols. DNA methylation typically represses gene transcription. Analytic laboratory methods used to measure DNA methylation depend on the scope of the measure of interest, for example, global methylation (liquid chromatograph-mass spectrometry), candidate genes/regions (pyrosequencing of bisulfite-treated DNA), epigenome-wide loci (n=≈850 000 in current methylation arrays), or in the entire genome sequence (whole-genome bisulfite sequencing). Histone modifications can have profound effects on any chromatin-dependent process, including DNA repair, replication, and expression. Histone modifications can also be measured globally (Western blot analysis with antibodies raised against specific histone modifications) or in genes/regions that a protein of interest is associated with (chromatin immunoprecipitation followed by microarrary or sequencing techniques). Epigenetic studies of disease have typically sought to discover associations between differentially methylated DNA regions or specific histone modifications and disease phenotypes.
Although largely animal models have been used to study methylation of genes known to play a role in BP homeostasis, a few candidate gene studies in humans have also been illustrative. For example, in a small case (N=150)-control (N=100) study of essential hypertension, Bayoumy et al measured DNA methylation in whole blood in 5 cytosine-phosphate group-guanine sites (CpGs) in the ADD1 promoter region. ADD1 encodes α-adducin; ADD1 sequence variants have been associated with hypertension. They found that lower methylation levels were associated with greater hypertension risk, although the predictive CpGs varied between men and women. 18 In a sample of 32 normotensive glucocorticoid-treated patients and 25 treated hypertensives, Friso et al measured associations between HSD11B2 promoter methylation (in peripheral blood mononuclear cells) and urinary tetrahydrocortisol-tetrahydrocortisone ratio-a marker of 11β-HSD2 enzyme activity. Decreased 11β-HSD2 activity ultimately causes renal sodium retention and increased BP. Higher promoter methylation was associated with higher tetrahydrocortisol-tetrahydrocortisone ratio in both groups and development of hypertension in the initially normotensive group. 19 Both of these studies illustrate the potential importance of epigenetic regulation of gene expression/repression in hypertension pathophysiology
Although target-gene studies, such as these, can help characterize the role of known or suspected factors in BP homeostasis, agnostic epigenome-wide association studies can potentially identify genes and mechanisms previously unstudied in the context of hypertension. To date, few of these epigenomic studies have been done. In one, Richard et al measured methylation throughout the genome in either wholeblood samples or isolated CD4
+ cells for a 2-stage association meta-analysis of SBP and DBP in participants of African, European, and Hispanic ancestry. Of the 31 CpGs identified during the discovery stage (N=9828), 13 were significant for at least 1 phenotype in the replication stage (N=7182) after correction for multiple testing. The replicated CpGs were heritable (>30%), and many were in genes not previously associated with BP. Mendelian randomization analyses revealed that, in some cases, methylation influenced BP (eg, at a CpG in ZMIZ1); in other cases, BP influenced methylation (eg, at a CpG in CPT1A). In several cases, gene expression was found to be a mediator of association between methylation and BP (eg, methylation at cg23999170 in TSPAN2). 20 Studies of post-translational histone modification in the context of BP and hypertension have been few, and most have been in animal models 21 and cell cultures. 22 This early work hints at potential clinical application, including using histone deacetylases as antihypertensive agents. 23 
Transcriptomics
Transcriptomics seeks to identify and quantify all RNA transcripts (potentially including messenger, transfer, ribosomal, and noncoding regulatory RNAs) produced by a cell or organism under specific conditions. Whereas DNA sequence genomics can reveal the comprehensive transcriptional potential of an organism, transcriptomics provides a snapshot of which genes are actively being expressed by a cell or tissue at a given time. The 2 primary transcriptomic laboratory methods currently in use include microarrays and RNA-Seq. The older microarray method makes use of the same technologies used in the genome-wide DNA microarrays noted above, typically by quantifying RNA as complementary DNA after reverse transcription. RNA-Seq makes use of high-throughput, next-generation technologies to sequence complementary DNA. Microarrays are less expensive than RNA-Seq methods.
However, reference transcripts are required to create probes for the microarray; therefore, this method can quantify transcripts only for organisms with a known and annotated genome sequence. RNA-Seq has no such requirements and can, therefore, quantify novel sequences and detect splice variants. 24 Of course, the transcriptome varies among tissues from the same organism. Choice of sample matrix depends on factors such as accessibility and study objectives. Typically, transcriptomic studies compare gene expression profiles under ≥2 different experimental conditions, such as different environmental exposures or different disease states. There are several ways to analyze transcriptomic data. Heat maps offer a simple way to visually display differences in expression between experimental conditions. Gene coexpression network analysis can characterize regulatory programs and associate genes of unknown function with metabolic processes. Pathway analysis uses information cataloged in functional gene annotation databases to identify metabolic, signaling, and gene regulatory pathways that may be in play with a given gene expression pattern.
A recent investigation by Basu et al analyzed transcriptomic profiles in 29 tissues from 565 participants with known hypertension status. They found that differentially (ie, in hypertensives versus normotensives) expressed genes were generally tissue specific, with an average 4% overlap between any 2 tissues. Using least absolute shrinkage and selection operator-a method for linear regression, they found 7 tissues in which expression profiles of differentially expressed genes could predict hypertension status significantly better than randomly selected genes (maximum area under the receiver operating characteristic curve, 0.75). Functional enrichment analysis of differentially expressed genes identified several pathways with a priori associations with BP (eg, fatty acid metabolism, insulin signaling). Genes previously linked to hypertension status (from GWAS, animal models, computational prediction, etc) tended to be differentially expressed in the study by Basu et al. They noted that SNPs within expression quantitative trait loci in differentially expressed genes were often associated with BP in a GWAS consortium study, thus suggesting transcriptomic factors were, in part, responsible for genotypic associations with BP. Finally, these investigators found hypertensive individuals largely fell into 1 of 2 subgroups: those in the diffused group demonstrated transcriptional alterations in many tissues, whereas the localized group had alterations in only a few tissues. 25 A recent and ambitious study by Zeller et al used a discovery and replication meta-analysis of 4 population-based studies to identify transcripts associated with BP-related traits. Suggestive findings from the discovery phase, which made use of monocyte gene expression data from the Gutenberg Health Study (N=1285) and the Multi-Ethnic Study of Atherosclerosis (N=1264), were moved forward for replication in the Health in Pomerania-SHIP-TREND (Study of Health in Pomerania-TREND; N=997) and KORA (Cooperative Heath Research in the Region Augsburg; N=993) studies. Eight transcripts met criteria for replication (5 for association with SBP, 6 for DBP, and 3 for pulse pressure). The associations between transcripts and BP phenotypes remained significant after excluding those treated with antihypertensives and when including only white participants. The variance in BP traits attributable to gene expression ranged from 1.36% to 11.33%.
In an analysis of participants with baseline and 5-year followup BP phenotype data, Zeller et al found strong associations with 5-year change in BP trait and 7 of the 8 transcripts identified in the meta-analysis. In an analysis of association of transcript levels with BP reduction after 6-month treatment with antihypertensives, they found 7 of the 8 candidates had significant reductions in transcription with treatment. The strongest response in all of the BP modulation analyses was for CRIP1 (cysteine-rich protein 1), whose transcription level was also associated with cardiac hypertrophy phenotypes. These investigators also assessed the predictive value of circulating CRIP1 and found a significant association between protein levels and incident stroke. 26 Both of the aforementioned studies investigated phenotype associations with messenger RNA transcripts. Other forms of RNA have been studied in the context of BP. For example, Zhang et al examined associations between BP and increases in microRNA (miRNA) expression. miRNAs are small, noncoding molecules that play a role in gene expression. Zhang et al quantified 166 miRNAs in 120 Beijing truck drivers and office workers who completed prework and postwork BP exams. In an analysis that pooled all participants, 23 miRNAs were associated with prework BP. In analyses that stratified by risk group, overlapping groups of miRNAs were associated with prework BP in high body mass index participants, truck drivers, and usual alcohol drinkers. Postwork BP was associated only with miRNAs in ever smokers. 27 Circular RNA 28 and mitochondrial transfer RNA 29 have also been explored in the context of hypertension. Although transcriptomics poses several unique challenges to researchers (eg, RNA is much less stable than DNA, validation with real-time quantitative polymerase chain reaction is complex and expensive, current statistical approaches cannot capture the complexities of regulatory networks), these studies suggest the approach holds much promise.
Proteomics
Proteomics is the study of the full complement of proteins produced or modified by a biological system (cell, tissue, organ, biological fluid, or organism). Proteomic species occupy a position downstream from genomic and transcriptomic processes. Although the human genome contains some 20 300 genes, differential translation and splicing, amino acid polymorphisms, as well as post-translational modification (eg, acetylation, phosphorylation, glycosylation) can result in as many as ≈100 different proteins stemming from a single gene. 30 Proteins are functional molecules; as such, differences among proteins can be correlated with activity and function within biological systems. Proteomic species can be identified and quantified using several analytic laboratory approaches, including liquid chromatography-tandem mass spectrometry, isotope-coded protein labeling, and protein microarrays. Like the transcriptome, the proteome varies among tissues. As a sample matrix, the human plasma proteome offers several advantages, especially in the context of hypertension-plasma is readily available and potentially contains markers of most physiological and pathological states. However, plasma proteomics also presents several challenges. For example, the plasma proteome is complex, potentially comprising >300 000 polypeptide species. 31 This presents technical challenges both in the laboratory and during statistical analysis. The enormous range in concentrations (as many as 10 orders of magnitude) between high-abundance proteins, such as albumin, and rare proteins, such as tumor necrosis factor-α, also poses technical challenges. 32 Virtually, every choice made in the design of an analytic pipeline, such as which anticoagulant used to prepare plasma specimens, can lead to variable results and lack of comparability among studies. 33 Given the importance of renal function in BP regulation, the urine proteome, which is considerably less complex and more stable than plasma, is another attractive option for the study of hypertension. Global proteomic methods attempt to separate, identify, and quantify all proteins in a specimen. This hypothesis-generating approach can use either bottom-up (analyzing peptide fragments derived from parent proteins) or top-down (analyzing intact proteins) strategies. Only the top-down method is able to identify all the post-translational modifications present on a protein molecule. 34 Targeted proteomic methods identify and quantify a limited number of species but often have greater sensitivity and higher throughput than global methods. 35 As with transcriptomic data, proteomic data can be subjected to both pathway and network analyses. 36 The number of proteomic studies of hypertension is limited. A recent study by Gajjala et al performed plasma proteomics on 118 hypertensive cases (diagnosed before 50 years of age) and 85 normotensive controls in the InGenious HyperCare cohort. Using mass-spectrometric and other methods, these investigators identified 12 926 proteomic species. Of these, least absolute shrinkage and selection operator logistic regression selected 27 that were predictive for case-control status. They found that downregulation of 19 species and upregulation of 8 species were associated with a higher probability of hypertension. The diagnostic power of these species was assessed with receiver operating characteristic analysis: the area under the curve was 0.89 (95% confidence interval, 0.85-0.93; P<0.0001), indicating excellent discriminatory ability. Using mass spectrometry, 18 of the 27 species were identified. Although these investigators were judiciously agnostic in discussing causal relationships between the lipidomic species and hypertension, they did note that some of the identified species have known or probable roles in BP regulation and cardiovascular pathologies. For example, phospholamban and sarcolipin play roles in calcium metabolism and vessel contraction, osteocalcin and humanin have been implicated in atherogenesis, and nexilin and palladin are involved with cytoskeletal organization and regulation. Overall, Gajjala et al 37 demonstrated the hypothesis-generating power of proteomics in the context of hypertension with findings that can be further explored in in vivo models.
Proteomic studies of specific forms of hypertension have been more abundant than those of primary hypertension. For example, Matafora et al 38 conducted a salt-loading intervention in newly diagnosed, never-treated, mild hypertensive men. Individuals were categorized as salt resistant (N=10) or salt sensitive (n=7) based on mean BP changes after saline infusion. A group of 7 normotensive controls was also included in the proteomic study. Liquid chromotography-tandem mass spectrometry was used to quantify 812 protein groups. May 11, 2018
Fifty-six proteins were differentially present in both saltsensitive and salt-resistant hypertensives compared with controls; other proteins were excreted differently in salt-sensitive compared with salt-resistant individuals. Bioinformatic analyses found an enrichment of proteins related to glycolysis-a pathway, the authors claimed, not previously implicated in hypertension. Follow-up studies of candidate proteins found different uromodulin levels in both hypertensive groups compared with controls. Nephrin 1-a structural protein involved in renal filtration whose defects cause a form of congenital kidney failure-was predictive of the salt sensitivity. Although the uromodulin and nephrin 1 findings are more confirmatory than novel, this study suggests the urine proteome may offer keys to understanding salt-sensitive hypertension.
Given that the pathogenesis of preeclampsia remains largely unknown and the diagnosis can be difficult, proteomic explorations of this hypertensive disorder may uncover novel pathophysiological mechanisms and diagnostic markers. 39 In an early investigation, Buhimschi et al performed urine proteomics on 284 women in a 3-stage (exploratory, challenge, translational) study. Proteomic profiles were generated using surface-enhanced laser desorption/ionization; peptide species were identified using tandem mass spectrometry. Preeclampsia severity was associated with the presence of a 21-aa C-terminus fragment of SERPINA-1 (serpin peptidase inhibitor 1) fragments of albumin. This proteomic fingerprint appeared in the urine before the appearance of clinical symptoms and was significantly better than traditional clinical evaluation in predicting the severity of preeclampsia. 40 A good number of other proteomic studies have advanced our ability to predict, diagnose, and understand the pathophysiology of preeclampsia. [41] [42] [43] [44] The American Heart Association published a 2015 scientific statement on proteomics that predicted the approach would have a transformative impact on cardiovascular health and disease. Although much of the discussion in the statement centered around organ disease, the authors predict proteomics will increase our understanding of the pathogenesis and progression of hypertension and will someday be used to monitor the efficacy of antihypertensive treatment. 45 
Metabolomics
Metabolomics is the study of endogenous and exogenous small (typically 50-1500 Da) molecules comprising the substrates and products of metabolic processes. The metabolome is the aggregate of all metabolites in a biological system. Examples of such metabolites include amino and fatty acids, lipids, sugars, and phenolic compounds. The Human Metabolome Database 46 currently contains >114 100 entries. Like the transcriptome and proteome, the metabolome is cell and tissue specific. Several analytic laboratory approaches are used to characterize the metabolome, including mass spectrometry and nuclear magnetic resonance spectroscopy. Some methods affect chemical separation (eg, by gas chromatography or high-performance liquid chromatography) before detection, whereas others do not (shotgun metabolomics). Global (or untargeted) metabolomics methods can provide data on 1000+ metabolites, whereas targeted methods typically assay a particular class of molecules (eg, lipids). The metabolome can adapt quickly to physiological, pathophysiological, and environmental conditions, thereby providing a snapshot of an organism's current status.
Kulkarni et al profiled 319 lipid species in 1192 MexicanAmerican participants from the San Antonio Family Heart Study. Polygenic regression and liability threshold models were used to investigate associations between plasma lipid profile and BP and hypertension. Fourteen lipid species (3 monohexosylceramides, 3 phosphatidylinositols, 7 diacylglycerols, and a phosphatidylcholine) were significantly associated with DBP, SBP, and mean arterial pressure. Phosphatidylethanolamine 40:6 and diacylglycerols 16:0/22:5 and 16:0/226 were also associated with risk of incident hypertension (mean follow-up, ≈6 years). 47 Zheng et al explored associations between incident hypertension and 204 metabolites in ≈900 blacks in the Atherosclerosis Risk in Communities cohort. Participants were normotensive at baseline, and 38% developed hypertension during the ≈10-year follow-up. Risk of hypertension increased by 17% for each 1-SD increase of 4-hydroxyhippurate above baseline. 48 4-Hydroxyhippuric acid results from polyphenol metabolism by gut microflora. 49 Principal component analyses found a significant association between incident hypertension and a sex steroid pattern; nominally significant predictors of incident hypertension included epiandrosterone sulfate, 5 α-androstan-3β 17β-diol disulfate, and androsterone sulfate. 48 Menni et al explored associations between 280 fasting blood metabolites and BP and all-cause mortality in ≈4000 female participants of the TwinsUK study. The dicarboxylic acid hexadecanedioate was associated with both BP (SBP: β=1.31, 95% confidence interval=0.83-1.78, P=6.81×10 −8 ; DBP: β=0.81, 95% confidence interval=0.5-1.11, P=2.96×10 −7 ) and mortality (hazard ratio, 1.49; 95% confidence interval, 1.08-2.05; P=0.02). These findings were replicated in the independent KORA (N=1494) and Hertfordshire (N=1515) studies. Three independent animal experiments in Wistar-Kyoto rats suggested the hexadecanedioate→BP relationship is causal. 50 A recent genomic and transcriptomic follow-up study by the same group sought to uncover molecular pathways associated with BP and hexadecanedioate levels. They found that levels of enzymes in the omega oxidation pathway (ADH1A, ADH1B, and CYP4) were correlated with hexadecanedioate levels and that high circulating levels of hexadecanedioate explain a significant portion of ethanol's effect on BP (SBP: β=1.12, SE=0.34, P=0.001; DBP: β=0.70, SE=0.22, P=0.002). 51 Randomly selected serum blood samples from 135 cases and 981 noncases from the European Prospective Investigation Into Cancer and Nutrition-Potsdam cohort were used in a metabolomics study of incident hypertension. Blood samples were drawn from nonhypertensive participants who were followed for an average of 9.9 years. Targeted metabolomic data were analyzed to identify which of the 127 metabolites predicted incident hypertension. Serine, glycine, and acylalkyl-phosphatidylcholines C42:4 and C44:3 were positively associated and diacyl-phosphatidylcholines C38:4 and C38:3 were negatively associated with predicted 10-year hypertension-free incidence. 52 These findings await independent replication and functional follow-up.
A recent study by Ameta et al compared serum samples from 64 essential hypertensive patients with 59 healthy controls. Principal component analysis and orthogonal partial least squares discriminant analysis of metabolome data revealed that alanine, pyruvate, methionine, arginine, adenine, and uracil differed significantly between cases and controls. Although they did not test the discriminating power of these 6 factors in an independent population, these metabolites could correctly classify the study's cases and controls with a sensitivity of 99% and a specificity of 99%. 53 Several other studies have successfully applied metabolomic techniques to characterize incident and prevalent hypertension and discover potential etiologic pathways involving lipid 54, lipid 55, amino acid, 54 and alcohol 55 metabolism; inflammation 56 ; immune 57 and renal 58 function; and diet and microbiome. 59, 60 An important area for future work will be pharmacometabolomics. Several studies have demonstrated the utility of metabolomic approaches in monitoring antihypertensive treatment adherence. 61, 62 Other work in this area has begun to characterize response to antihypertensive drugs with the hope of one day improving treatment decisions.
63-65

Integrative Omics
The wealth of omic data has created a wave of interest to integrate the various types of data into comprehensive statistical models. The goal of omic integrative models is to identify molecular mechanisms, cluster samples, and predict outcomes. To infer complex biological processes related to blood pressure regulation or hypertension, data derived from multiple sources should be integrated and analyzed. This systems biology approach to understanding omic influences on BP regulation, hypertension, or response to treatment is particularly challenging; nonetheless, it is one of the most relevant problems facing computational scientists today. At a superficial level, integration seems to offer obvious benefits for better understanding functional pathways and regulatory networks for BP and hypertension. However, at an implementation level, integration is difficult to achieve because of the inherent complexity of biological systems. First, each molecular platform (ie, genomics, epigenomics, transcriptomics, proteomics, and metabolomics) provides measures of different biological inputs to disease, and second, these biological inputs are not independent of one another, complicating traditional statistical approaches. A third challenge is that data are often represented by a large number of variables coupled with a small number of samples, resulting in highly dimensional data.
There has been some progress in creation of analytic methods that provide integration of omic data, and the field continues to expand with new methods. These methods can generally be categorized into approaches that are unsupervised (eg, gene set and pathway-based analyses, some of which use artificial intelligence approaches 66 ) or supervised (eg, computational pipelines where a sequence of tasks is performed, eg, building from genomics to transcriptomics to proteomics). To date, there are no published reports of an unsupervised approach in the area of BP regulation or hypertension. However, there is an example of a sequential approach applied to pulse wave velocity. 67 Mangino et al identified an SNP in the CIB2 that associated with pulse wave velocity. Subsequently, they explored whether this same variant was associated with increased CIB2 expression (ie, transcriptomics) and with methylation of the gene promoter (ie, epigenetics). Mangino et al reported that reduced methylation of the CIB2 promoter in individuals with the rs7164338 variant may lead to increased expression of CIB2 and hypothesized that the role that the gene plays in regulation of intracellular calcium may prevent he accumulation of serum calcium and phosphate, ultimately slowing down the rate of vascular calcification. Clearly, there is much work to be done in creating the right statistical tools to conduct multiomic modeling and applying these models to BP and hypertension.
BP and Hypertension Omics: Where We Stand Today
Given the resources that have been committed to studying the omics of BP and hypertension, it is reasonable to ask the extent to which omic approaches have impacted or are likely to impact clinical practice. When posing this question, it is important to remember that clinical impact can be direct or indirect. That is, omic methods might be used directly in the clinic to predict and stratify risk, aid diagnosis, and guide treatment decisions. For example, 1 clinical program (albeit highly experimental) has successfully used whole-genome sequencing to diagnose suspected genetic disorders. 68 We are unaware of any other omic approaches that have yet undergone the necessary vetting for routine clinical use, including any that might have a direct impact on hypertension risk stratification or treatment guidance. It should be obvious that omic approaches are unlikely to play a role in hypertension diagnostics.
Indirect clinical impacts include new clinical measures that derive from omic research but do not involve omic measures in the clinical setting. Examples of this might include a new drug developed from a deeper understanding of renal function gained through metabolomics research, a genetic risk score assay, or a pharmacogenomic assessment developed from genomic association studies. In cancer clinics, for example, the use of multigene expression panels-with origins in genomic and transcriptomic research-has become common when making decisions regarding adjuvant therapy in breast cancer. 69 Although the indirect impact of omics in the context of BP and hypertension is currently negligible, it is via this route that omics may have the greatest potential impact. For example, given the potentially lifelong effect of genetic variants, genetic risk scores might be used to predict hypertension and related cardiovascular disease (CVD) before it develops. One study made use of a panel of 32 SNPs previously identified via BP GWAS to create a genetic risk score. After 9.8-year mean follow-up, the score significantly and independently predicted increased risk of coronary heart disease, stroke, and CVD. 70 Although no pharmacogenomic or pharmacometabolomic prescribing regimens for hypertension have been developed to date, this is another area of intense research and optimism. 65 
Limitations and Challenges
The optimism for as-yet unmade omic discoveries should not, however, blind us to the significant challenges that stand between the status quo and routine clinical utility. Perhaps the greatest challenge is posed by the epiphenomenal nature of the BP and hypertension phenotypes themselves. The clinical value of BP measurements is indisputable: hypertension's status as a risk factor for CVD is supported by decades of research. But BP homeostasis and hypertension result from the interaction of numerous, incompletely understood, underlying metabolic pathways. In this sense, studying the omics of hypertension is fundamentally different than studying the omics of cancer: cancer is a class of disease, hypertension is a risk factor for a class of diseases. The difficulties caused by the epiphenomenal nature of BP and hypertension phenotypes have been acutely evident in genomics research; to date, few variants found to be associated with BP in GWAS have been functionally linked to underlying molecular pathways. 71 This functional research is a necessary and crucial step in translation of omic findings into something of clinical relevance. Many omic investigations are hypothesis-generating association studies that simply (albeit critically) seek correlations between biomarkers and health and disease phenotypes: a metabolomics study that finds an association between an elevated steroid level and hypertension, for example, does not prove the steroid causes hypertension (or vice versa). For this, functional follow-up studies (along with literature mining) that dissect and characterize the role of the biomarker in a physiological pathway are necessary. Research in animal models and human cell lines are 2 common modes of functional followup. 72, 73 The hope is that the more complete picture of a disease phenotype (eg, BP) provided by all omics collectively along with the necessary follow-up work will suggest new avenues of prevention, prediction, and treatment that could ultimately be validated in clinical trials. 74 In this sense, omic research represents a first step in a long process of discovery, validation, characterization, and translation.
The complex nature of BP phenotypes and their relationship to CVD and the necessity of functional follow-up research are not the only difficulties faced by omic researchers. All omic investigations are big data enterprises, requiring large amounts of digital storage, immense computing power, and the statistical expertise necessary to work with large data sets. A modest whole-genome sequencing study of 1000 participants, for example, requires 200 to 300 TB of data storage space (including backup). Storage demands for other omics are considerably less but still substantial (and likely to grow for proteomic and metabolomics studies). Many studies rely on commercial, cloud-based storage services, such as Google Genomics (http://cloud.google.com/genomics/), Amazon Web Services (http://aws.amazon.com/health/genomics/), and Microsoft Genomics (http://enterprise.microsoft.com/en-us/ industries/health/genomics/). These services provide safe, secure access to data for large research teams and facilitate data sharing among research groups. Systems that make use of artificial intelligence have been developed to streamline computationally demanding data processing 75 ; these approaches are beginning to make inroads in CVD research.
76 Figure 2 lists the generally recognized limitations and challenges faced by each omic discipline and omics in general.
Conclusion
Hypertension remains a significant public health threat, and the identification of the omic contributions to BP and hypertension remains a critical area of inquiry. The multiomic field of hypertension is in its infancy, and much attention needs to be directed to leveraging the tremendous gains in the technological aspects of omic-based platforms with new methods for discovery of biologically meaningful mechanisms. Next-generation sequencing, epigenomics, proteomics, and metabolomics are poised to make discoveries that will increase our understanding of BP homeostasis, which may, in turn, lead to new treatments and screening methods that can predict who is at risk of developing hypertension and targetorgan damage. Thoughtful scientists with knowledge of biology coupled with imaginative data analysts are needed to address this new and emerging field. As suggested in 1991 in a review article of the molecular biology of hypertension by Krieger and Dzau, 77 BP is controlled by multiple systems, including vascular, cardiogenic, renal, neurogenic, and endocrine mechanisms that interact in a complex but integrated manner to achieve BP homeostasis, and multiple proteins and metabolites are thought to regulate these control systems. As we move into the era of agnostic omic approaches, we must apply our imagination and precise scientific approaches to illuminate the intricate web of omic contributions to BP.
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